Generation Investment Management LLP Makes New Investment in Stryker Corporation $SYK

Generation Investment Management LLP purchased a new stake in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 512,346 shares of the medical technology company’s stock, valued at approximately $161,307,000. Stryker accounts for about 1.6% of Generation Investment Management LLP’s holdings, making the stock its 18th largest position. Generation Investment Management LLP owned approximately 0.13% of Stryker as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after acquiring an additional 133,892 shares during the last quarter. State Street Corp raised its stake in shares of Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after acquiring an additional 311,507 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares during the period. Wellington Management Group LLP raised its holdings in Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares during the period. Finally, Norges Bank acquired a new position in shares of Stryker during the 4th quarter worth about $1,822,272,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK stock opened at $340.20 on Thursday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $130.49 billion, a price-to-earnings ratio of 35.25, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The firm has a fifty day moving average of $326.19 and a 200-day moving average of $332.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the firm posted $3.13 earnings per share. Stryker’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is 36.48%.

Analyst Ratings Changes

SYK has been the subject of several research analyst reports. Needham & Company LLC cut their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Citigroup restated a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. Truist Financial boosted their price target on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Finally, BTIG Research decreased their price target on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 315,370 shares of company stock worth $98,463,501. 4.60% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.